Novel HER2 Selective Tyrosine Kinase Inhibitor, TAK-165, Inhibits Bladder, Kidney and Androgen-Independent Prostate Cancer in Vitro and in Vivo

International Journal of Urology - United Kingdom
doi 10.1111/j.1442-2042.2006.01342.x
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Wiley-Blackwell

Related search

P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth in Vivo

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and Is Synergistic With Trastuzumab in Vitro and in Vivo

Clinical Cancer Research
Cancer ResearchOncology
2010English

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Scientific Reports
Multidisciplinary
2019English

MP470, a Novel Receptor Tyrosine Kinase Inhibitor, in Combination With Erlotinib Inhibits the HER Family/Pi3k/Akt Pathway and Tumor Growth in Prostate Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2009English

Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

Clinical Cancer Research
Cancer ResearchOncology
2011English

Retraction: Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol 3-Kinase-Mediated Akt Signaling in Androgen-Independent Prostate Cancer Cells

Cancer Prevention Research
MedicineCancer ResearchOncology
2011English

Hedgehog Signalling in Androgen Independent Prostate Cancer

European Urology
Urology
2008English

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and in Vivo Characterization

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy